Remote Buying of ALPS Fund Services - ALPS Medical Breakthroughs ETF through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of ALPS Fund Services - ALPS Medical Breakthroughs ETF through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Opsens: The Making Of A Diversified Medical Technology Company via Seeking Alpha
Treace Medical Concepts Seeks U.S. IPO via Seeking Alpha
The PNC Financial Services Group, Inc. (PNC) CEO Bill Demchak on Q1 2021 Results - Earnings Call Transcript via Seeking Alpha
Global Medical REIT started at outperform with $16 stock price target at BMO Capital via MarketWatch
The PNC Financial Services Group, Inc. 2021 Q1 - Results - Earnings Call Presentation via Seeking Alpha
As Real Estate Investors Targets Medical Property, Watch ‘DRN’ via ETF Trends
Brian Brooks defends fintech charter to House Financial Services Committee via Cointelegraph
KLX Energy Services Holdings, Inc. (KLXE) CEO Chris Baker on Q4 2020 Results - Earnings Call Transcript via Seeking Alpha
West Pharmaceutical Services - Should You Be Paying A Premium Multiple? via Seeking Alpha
OncoSec Medical stock price target raised to $11.00 from $6.50 at Alliance Global via MarketWatch
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
Analysis is available when the exchange & market are open.